Ausgabe 3/2017
Inhalt (15 Artikel)
Development of chemotherapeutics in oncology: is there anything new?
Holger Rumpold, Thomas Winder
An Austrian view of the 2017 consensus for the treatment of early breast cancer
Guenther G. Steger
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Markus Kieler, Matthias Unseld, Daniela Bianconi, Gerald W. Prager
Renal insufficiency in patients with multiple myeloma
Boris Bozic, Sophie Hölbling, Vanessa Völkel, Christian Sebesta
Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
Branka Petricevic, Wolfgang Hilbe, Niklas Zojer
Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
Maria Kavianpour, Neda Ketabchi, Najmaldin Saki
Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
Sonja Burgstaller, Josef Thaler
Highlights from the 2017 St. Gallen Breast Cancer Consensus
Georg Pfeiler, Rupert Bartsch, Florian Fitzal
New diagnostic tools for breast cancer
Pascal A. T. Baltzer, Panagiotis Kapetas, Maria Adele Marino, Paola Clauser